[Trial of a new antiepileptic drug, magnesium dipropyl acetate]. 1973

E G de Pasquet, and J B Gomensoro, and L F de Bustos, and S M Tenzer

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D004827 Epilepsy A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313) Aura,Awakening Epilepsy,Seizure Disorder,Epilepsy, Cryptogenic,Auras,Cryptogenic Epilepsies,Cryptogenic Epilepsy,Epilepsies,Epilepsies, Cryptogenic,Epilepsy, Awakening,Seizure Disorders
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D014631 Valerates Derivatives of valeric acid, including its salts and esters. Pentanoate,Pentanoates,Valerate

Related Publications

E G de Pasquet, and J B Gomensoro, and L F de Bustos, and S M Tenzer
May 1979, Ceskoslovenska pediatrie,
E G de Pasquet, and J B Gomensoro, and L F de Bustos, and S M Tenzer
January 1971, Deutsche medizinische Wochenschrift (1946),
E G de Pasquet, and J B Gomensoro, and L F de Bustos, and S M Tenzer
September 1967, Minerva medica,
E G de Pasquet, and J B Gomensoro, and L F de Bustos, and S M Tenzer
April 2002, Journal of neurology, neurosurgery, and psychiatry,
E G de Pasquet, and J B Gomensoro, and L F de Bustos, and S M Tenzer
January 1964, Medicinski pregled,
E G de Pasquet, and J B Gomensoro, and L F de Bustos, and S M Tenzer
January 2003, Polish journal of pharmacology,
E G de Pasquet, and J B Gomensoro, and L F de Bustos, and S M Tenzer
March 1949, La Diagnosi; rivista mensile di medicina pratica,
E G de Pasquet, and J B Gomensoro, and L F de Bustos, and S M Tenzer
October 1997, The Annals of pharmacotherapy,
E G de Pasquet, and J B Gomensoro, and L F de Bustos, and S M Tenzer
August 1997, Revista de neurologia,
E G de Pasquet, and J B Gomensoro, and L F de Bustos, and S M Tenzer
April 1994, Drug and therapeutics bulletin,
Copied contents to your clipboard!